Of the 106 immune signatures studied, five showed significant links to lung cancer subtypes, including CD25 on IgD- CD24- cells in SCLC, CD27 on IgD+ CD24+ cells in LUSC, CCR2 on monocyte cells in LUSC, CD123 on CD62L+ plasmacytoid DCs in LUSC, and CD123 on plasmacytoid DCs in LUSC, pointing to their roles in cancer development. Here, SELL is linked to small cell lung carcinoma.